The FDA's agreement on a streamlined path to approval based on a single Phase 3 trial significantly de-risks the development pathway for nebokitug. Traders should monitor upcoming Phase 3 initiation, partnership developments, and clinical event accrual. The strong biomarker data and regulatory designations (Orphan Drug, Fast Track) increase the likelihood of commercial success if Phase 3 confirms clinical benefit.
CMMB drugs
CMMB drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $1.93entry
- T+1 · 8mo ago −7.77%α −6.03% · $1.78
- T+5 · 8mo ago −19.69%α −17.48% · $1.55
- T+20 · 7mo ago −13.47%α −21.09% · $1.67
- T+60 · 5mo ago −18.13%α −32.48% · $1.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab Therapeutics reported its full-year and Q4 2025 financial results, highlighted by a successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), alignment on a single Phase 3 trial for potential approval, and strong clinical data presentations. The company has $10.4M in cash, sufficient to fund operations into Q1 2027, while R&D expenses declined due to completion of its Phase 2 trial.
Key Financial Metrics
Key Facts
- FDA aligned with Chemomab on a single Phase 3 trial as a potential path to full approval for nebokitug in PSC, with a clinical event-driven primary endpoint.
- Phase 2 SPRING trial data published in peer-reviewed journals and presented at major liver disease conferences, including AASLD and DDW, with multiple 'posters of distinction' and a Best Oral Presentation award.
- Cash position was $10.4 million as of December 31, 2025, down from $14.3 million in 2024, but provides runway into Q1 2027.
- R&D expenses decreased to $5.8M in 2025 from $11.3M in 2024 due to completion of the Phase 2 trial.
- Net loss narrowed to $9.0M in 2025 from $13.9M in 2024.
- Shares outstanding increased to 575.4M from 377.1M due to financing activities, reflecting a reverse ADS split from 1:20 to 1:80 effective August 2025.
Financial Impact
Reduced R&D spend by $5.5M YoY and narrowed net loss by $4.9M, while maintaining sufficient cash runway into 2027 despite lower cash balance.
Risk Factors
- High reliance on a single asset (nebokitug) and indication (PSC), with no approved products yet.
- Future financing needs likely beyond Q1 2027, which could lead to dilution.
- Forward-looking statements highlight risks around FDA approval, clinical trial execution, manufacturing, and geopolitical exposure in Israel.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258911 |
Track record
15 reports on CMMB
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers